Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q7RTR2
UPID:
NLRC3_HUMAN
Alternative names:
CARD15-like protein; Caterpiller protein 16.2; NACHT, LRR and CARD domains-containing protein 3; Nucleotide-binding oligomerization domain protein 3
Alternative UPACC:
Q7RTR2; Q5EY36; Q8NF48; Q8NI01; Q8NI02; Q8TEL3
Background:
NLR family CARD domain-containing protein 3, also known as Nucleotide-binding oligomerization domain protein 3, plays a crucial role in regulating the innate immune response. It modulates signaling pathways activated by Toll-like receptors and the DNA sensor STING, impacting responses to pathogen-associated molecular patterns and DNA virus infections. This protein also influences the PI3K-AKT-mTOR pathway, affecting cell proliferation, especially in intestinal epithelial cells.
Therapeutic significance:
Understanding the role of NLR family CARD domain-containing protein 3 could open doors to potential therapeutic strategies.